Featured Research

from universities, journals, and other organizations

Best drug for ovarian cancer picked with use of genetics

Date:
February 18, 2014
Source:
University of Colorado Cancer Center
Summary:
There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. A sophisticated model of ovarian cancer genetics was used to match the right tumor with the right drug in a recent study. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

Because it has been so difficult to predict which ovarian cancers will respond to each of these three drugs, doctors have largely been forced to guess which will work best -- and so in this study of four groups of 783 patients each, some were accidentally given what would turn out to be the best possible drug whereas others were given one of the two other, less good drugs. The model, called COXEN (CO-eXpression gENe analysis), sorts through the massive genetic data of thousands of tumor samples to discover differences between tumors that responded and tumors that did not.

"The model allowed us to ask what would have been the right drug in each case, how could we have known from the tumor's genetics, and what difference it made," says Jennifer R. Diamond, MD, CU Cancer Center investigator and medical oncologist at the University of Colorado Hospital.

When COXEN looked back through this registry of advanced ovarian cancer, it first sorted tumors into those that had responded and those that had not responded to each drug ("what would have been the right drug in each case"). It then pinpointed genetic signatures of tumors that responded to each drug ("how could we have known from the tumor genetics"). And the study finally showed that patients who had been serendipitously given the drug that the COXEN model would have picked for them lived 21 months longer than the average patient with advanced ovarian cancer.

"We have traditionally considered site-specific cancer to be homogenous -- one ovarian cancer is like the next ovarian cancer. But we are increasingly learning that isn't the case at all. The COXEN model allows us to identify the heterogeneity within the disease. It lets us see why some ovarian cancers respond and others don't," Diamond says.

Diamond is also quick to point out that while the current study shows that COXEN could have been used to predict the most useful drug in many of these cases of advanced ovarian cancer, the actual use of the model will be possible only after validation with a prospective clinical trial. In fact, a similar strategy led to similar results in bladder cancer, and a prospective clinical trial of COXEN in bladder cancer is underway at the CU Cancer Center and elsewhere.

"This study supports the idea that we could test ovarian cancer tumors and say they're more likely to respond to one or the other drugs," Diamond says.


Story Source:

The above story is based on materials provided by University of Colorado Cancer Center. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Journal Reference:

  1. Youngchul Kim, Saketh R. Guntupalli, Sun J. Lee, Kian Behbakht, Dan Theodorescu, Jae K. Lee, Jennifer R. Diamond. Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer. PLoS ONE, 2014; 9 (2): e86532 DOI: 10.1371/journal.pone.0086532

Cite This Page:

University of Colorado Cancer Center. "Best drug for ovarian cancer picked with use of genetics." ScienceDaily. ScienceDaily, 18 February 2014. <www.sciencedaily.com/releases/2014/02/140218142354.htm>.
University of Colorado Cancer Center. (2014, February 18). Best drug for ovarian cancer picked with use of genetics. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/02/140218142354.htm
University of Colorado Cancer Center. "Best drug for ovarian cancer picked with use of genetics." ScienceDaily. www.sciencedaily.com/releases/2014/02/140218142354.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins